SCHEMBL1640565

SCHEMBL1640565

Cc1ccc(C)c(Cn2c(O)c(C(=O)Nc3cccnc3)c(O)c(C(=O)NCC(=O)O)c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.48
KDM4E B2RXH2 3/20 0.47
LMNA P02545 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TSHR P16473 1/20 0.47
EGLN1 Q9GZT9 3/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
BRAF P15056 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.40
RAB9A P51151 1/20 0.40
NAMPT P43490 3/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642619 0.93 EGLN3 (0.48) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1641145 0.92 EGLN3 (0.49) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1641581 0.87 EGLN3 (0.49) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1642420 0.84 EGLN3 (0.53) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1642196 0.84 EGLN3 (0.56) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1641217 0.78 HIF1A (0.51) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1641951 0.77 KDM4E (0.49) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1641432 0.74 EGLN3 (0.64) EGLN3KDM4EHTTALDH1A1EGLN1
SCHEMBL1641921 0.74 EGLN3 (0.58) EGLN3KDM4ELMNAHTTALDH1A1
SCHEMBL1640557 0.74 EGLN1 (0.53) EGLN3KDM4ELMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885KDM4E 521/4885LMNA 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.